Portland Investment Counsel Inc. acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 654 shares of the biopharmaceutical company’s stock, valued at approximately $408,000.
Several other hedge funds also recently modified their holdings of the stock. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $26,000. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth $29,000. Finally, Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals during the second quarter worth $29,000. Institutional investors own 83.31% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on REGN shares. Wells Fargo & Company upped their target price on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, HSBC dropped their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $801.70.
Insider Activity at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at $482,400. This represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,400 shares of company stock worth $1,090,030. Corporate insiders own 6.97% of the company’s stock.
Regeneron Pharmaceuticals Price Performance
Shares of NASDAQ REGN opened at $834.04 on Monday. The firm has a market cap of $85.87 billion, a P/E ratio of 20.61, a price-to-earnings-growth ratio of 1.42 and a beta of 0.21. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $847.00. The business’s 50 day moving average is $697.09 and its 200-day moving average is $716.46.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the company posted $12.81 EPS. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.
Regeneron Pharmaceuticals Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.
Trending Headlines about Regeneron Pharmaceuticals
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
- Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
- Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
- Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
